PMID- 28617365
OWN - NLM
STAT- MEDLINE
DCOM- 20190408
LR  - 20190408
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 117
IP  - 2. Vyp. 2
DP  - 2017
TI  - [Immune reconstitution inflammatory syndrome and rebound syndrome in multiple 
      sclerosis patients who stopped disease modification therapy: current 
      understanding and a case report].
PG  - 74-84
LID - 10.17116/jnevro20171172274-84 [doi]
AB  - More and more multiple sclerosis patients have been receiving treatment with new 
      immunomodulatory drugs. Its discontinuation because of side-effects, lack of 
      efficacy or pregnancy has been increasing as well. This paper reviews such severe 
      complications of natalizumab and fingolimod cessation as immune reconstitution 
      inflammatory syndrome (IRIS) and rebound. The short history, immunopathogenesis 
      and diagnostic criteria of IRIS in individuals with human immunodeficiency virus 
      infection are covered. Clinical and radiological presentations as well as 
      possible pathogenic mechanisms of IRIS in patients treated with natalizumab and 
      fingolimod are discussed. The authors also report the case of a woman with 
      multiple sclerosis treated with fingolimod, who experienced a severe relapse when 
      she stopped treatment. Diagnostic criteria and prognostic factors for IRIS and 
      rebound are needed in patients with multiple sclerosis who discontinue the new 
      disease modification therapy.
FAU - Belova, A N
AU  - Belova AN
AD  - Privolzskyi Federal Medical Research Center, Nizhny Novgorod, Russia.
FAU - Rasteryaeva, M V
AU  - Rasteryaeva MV
AD  - Privolzskyi Federal Medical Research Center, Nizhny Novgorod, Russia.
FAU - Zhulina, N I
AU  - Zhulina NI
AD  - Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia.
FAU - Belova, E M
AU  - Belova EM
AD  - Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia.
FAU - Boyko, A N
AU  - Boyko AN
AD  - Pirogov National Russian Scientific Medical University, Moscow, Russia ,Center 
      for demyelination diseases 'Neuroclinic', Moscow, Russia.
LA  - rus
PT  - Case Reports
PT  - Journal Article
PT  - Review
TT  - Vospalitel'nyi sindrom vosstanovleniia immuniteta i rebaund-sindrom pri otmene 
      nekotorykh preparatov immunomoduliruiushchei terapii rasseiannogo skleroza: 
      obshchie predstavleniia i sobstvennoe nabliudenie.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 0 (Immunologic Factors)
RN  - 0 (Natalizumab)
RN  - G926EC510T (Fingolimod Hydrochloride)
SB  - IM
MH  - Female
MH  - Fingolimod Hydrochloride/therapeutic use
MH  - Humans
MH  - *Immune Reconstitution Inflammatory Syndrome/etiology
MH  - *Immunologic Factors/therapeutic use
MH  - *Multiple Sclerosis/drug therapy
MH  - Natalizumab/therapeutic use
MH  - Pregnancy
MH  - Recurrence
OTO - NOTNLM
OT  - fingolimod
OT  - immune reconstitution inflammatory responses (IRIS)
OT  - multiple sclerosis
OT  - natalizumab
OT  - rebound
EDAT- 2017/06/16 06:00
MHDA- 2019/04/09 06:00
CRDT- 2017/06/16 06:00
PHST- 2017/06/16 06:00 [entrez]
PHST- 2017/06/16 06:00 [pubmed]
PHST- 2019/04/09 06:00 [medline]
AID - 10.17116/jnevro20171172274-84 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):74-84. doi: 
      10.17116/jnevro20171172274-84.